[go: up one dir, main page]

DE60302157D1 - Opioidrezeptorantagonisten - Google Patents

Opioidrezeptorantagonisten

Info

Publication number
DE60302157D1
DE60302157D1 DE60302157T DE60302157T DE60302157D1 DE 60302157 D1 DE60302157 D1 DE 60302157D1 DE 60302157 T DE60302157 T DE 60302157T DE 60302157 T DE60302157 T DE 60302157T DE 60302157 D1 DE60302157 D1 DE 60302157D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
opioid receptor
racemate
diastereomers
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60302157T
Other languages
English (en)
Other versions
DE60302157T2 (de
Inventor
Howard Mitch
James Quimby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60302157D1 publication Critical patent/DE60302157D1/de
Publication of DE60302157T2 publication Critical patent/DE60302157T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60302157T 2002-05-30 2003-05-22 Opioidrezeptorantagonisten Expired - Fee Related DE60302157T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38460302P 2002-05-30 2002-05-30
US384603P 2002-05-30
PCT/US2003/014540 WO2003101963A1 (en) 2002-05-30 2003-05-22 Opioid receptor antagonists

Publications (2)

Publication Number Publication Date
DE60302157D1 true DE60302157D1 (de) 2005-12-08
DE60302157T2 DE60302157T2 (de) 2006-07-27

Family

ID=29712067

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60302157T Expired - Fee Related DE60302157T2 (de) 2002-05-30 2003-05-22 Opioidrezeptorantagonisten

Country Status (7)

Country Link
US (1) US20050222204A1 (de)
EP (1) EP1513813B1 (de)
AT (1) ATE308522T1 (de)
AU (1) AU2003239389A1 (de)
DE (1) DE60302157T2 (de)
ES (1) ES2249722T3 (de)
WO (1) WO2003101963A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227135B2 (en) 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
AU2002329557B2 (en) 2001-10-22 2008-07-31 Pfizer Products Inc. 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
US20040204453A1 (en) * 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
DE602005012380D1 (de) * 2004-03-15 2009-03-05 Lilly Co Eli 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
US7538110B2 (en) * 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
AU2012200919B2 (en) * 2005-10-27 2015-05-28 Merck Sharp & Dohme Llc Novel opioid antagonists
CN101426481B (zh) 2006-04-21 2012-12-05 帝斯曼知识产权资产管理有限公司 阿片受体拮抗剂的用途
CA2662766C (en) 2006-09-08 2011-08-09 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
EP2152671A1 (de) 2007-05-22 2010-02-17 Prosidion Limited Bicyclische aryl- und heteroarylverbindungen zur behandlung von stoffwechselerkrankungen
EP2197835A1 (de) 2007-09-07 2010-06-23 Prosidion Limited Bicyclische aryl- und heteroarylverbindungen als rezeptormodulatoren
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
US20100311782A1 (en) * 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
HUE043963T2 (hu) 2009-12-04 2019-09-30 Alkermes Pharma Ireland Ltd Morfinán származékok gyógyszer-túladagolás kezelésére
JP5964809B2 (ja) 2010-03-22 2016-08-03 レンセラール ポリテクニック インスティチュート オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体
PT3446565T (pt) 2010-08-23 2024-01-29 Alkermes Pharma Ireland Ltd Métodos para tratar o aumento de peso induzido por antipsicóticos
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
EP2725908B1 (de) 2011-06-29 2017-05-31 Alkermes, Inc. Peripher wirkende opioidverbindungen
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
CA2858812C (en) 2011-12-15 2019-02-26 Alkermes Pharma Ireland Limited Compositions of buprenorphine and mu-opioid receptor antagonists
WO2014190270A1 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
GB9912411D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy

Also Published As

Publication number Publication date
DE60302157T2 (de) 2006-07-27
ATE308522T1 (de) 2005-11-15
EP1513813B1 (de) 2005-11-02
EP1513813A1 (de) 2005-03-16
ES2249722T3 (es) 2006-04-01
US20050222204A1 (en) 2005-10-06
AU2003239389A1 (en) 2003-12-19
WO2003101963A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
ATE406360T1 (de) Antagonisten der opioidrezeptoren
DE60302157D1 (de) Opioidrezeptorantagonisten
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
MY130803A (en) New quinuclidine amide derivatives
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
DK1663206T3 (da) 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imizadol-2-thion som ikke-sedativ alpha 2A-agonist
DE602004024375D1 (de) Carboxamidderivate
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
RS53895B1 (en) ATP-BINDING CASSETTE TRANSPORT MODULATORS
WO2004000808A3 (en) N-substituted piperidine derivatives as serotonin receptor agents
RS53428B (en) COMPOSITIONS AND ANTI-VIRUS ACTIVITY OF SUBSTITUTED AZAINDOLOXOSCETER PIPERAZINE DERIVATIVES
ATE399770T1 (de) Tachykininrezeptorantagonisten
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
WO2004082623A3 (en) Substituted piperidine compounds
DK1440059T3 (da) 3-azabicyclo(3.1.0)hexanderivater som opioidreceptorantagonister
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
DE60225694D1 (de) Fexofenadine hydrochlorid polymorph
MXPA05011476A (es) Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2004103305A3 (en) Spiropyrazole compound

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee